Bladder Cancer VL

Comparative Analyses of Costs and Survival Between Radical Cystectomy and Trimodal Therapy - Stephen Williams

Details
Ashish Kamat invites Stephen Williams to present on costs and survival analysis between radical cystectomy and trimodal therapy. He shares results of two studies which patients from 2002-2011 were looked at in both studies focusing on methodology/statistical analyses and the outline of outcomes. This work found that trimodal therapy had significantly worse survival, these findings persisted across...

Blue Light Cystoscopy with CYSVIEW: Improving Detection Rates of Bladder Cancer in the Clinic - Yair Lotan

Details
Yair Lotan discusses the advancements in the ability to detect bladder cancer and bladder cancer recurrence in the clinic with blue light cystoscopy. Until recently, the technology was only available in the OR but now, with the approval of blue light flexible cystoscopy bladder cancer surveillance can now be done in the clinic. The blue light cystoscopy with CYSVIEW is performed in the clinic to d...

Blue Light Cystoscopy (BLC™): What Urologist Want to Know - Anne Schuckman

Details
Anne Schuckman, MD presents the information that supports her decision to use blue light cystoscopy with CYSVIEW in the clinic. She takes us through the data of the studies and her experiences too. Biography: Anne Kathryn Schuckman, MD, Assistant Professor of Clinical Urology, Keck School of Medicine, USC, Dr. Anne Schuckman graduated from Stanford University and completed her medical training at...

Toxicity Management with Checkpoint Inhibitor Therapy - Thomas Powles

Details
Thomas Powles joins Charles Ryan discuss toxicity management and the most common toxicities you see in a bladder cancer population with checkpoint inhibitor therapy. Dr. Powles covers three main areas of toxicity management which include going twice as long once you've started immunosuppressants, starting steroids at a grade two toxicity, and the need to educate our patients to put them at the hea...

Bladder Cancer in Women - Morgan Roupret

Details
Morgan Roupret joins Charles Ryan to speak about the increase in bladder cancer in younger individuals and in particular younger women. Dr. Roupret explains the clinical issues that challenge clinicians when managing younger bladder cancer patients. Biographies: Morgan Roupret, MD, PhD, Professor of Urology, Sorbonne Université, Paris (UPMC), ESOU chairman, Paris, France Charles J. Ryan, MD , The...

BCG Shortage An Update - Jonathan Rubenstein

Details
Neal Shore and colleague, Jonathan Rubenstein provide an update on the advances and developments that have been communicated in regards to the truly important challenge of BCG shortage for the use of patients with a high-risk non-muscle invasive bladder cancer. This is an international problem. In a previous program Neal Shore, Ashish Kamat, and Jonathan Rubenstein talked about alternative dosing...

The Role of the Surgeon in the Treatment of Bladder Cancer - Jens Bedke

Details
Jens Bedke, MD discusses the multimodal approach for the treatment of bladder cancer from the surgeon's perspective. While cystectomy offers the greatest benefit to most patients, Dr. Bedke emphasizes the importance of differentiating patients, tumor types and tumor grades to guide patient care. Along with the role of neoadjuvant chemotherapy, Dr. Bedke discusses treatment approaches for the varia...

Immunotherapy in the Peri-Operative Setting for Bladder Cancer - Thomas Powles

Details
Thomas Powles, MD, and Charles Ryan, MD share in a discussion regarding the use of immunotherapy in the peri-operative setting for bladder cancer and the current state of immunotherapy for bladder cancer. Dr. Powles, while excited about the evolving role of immunotherapy, is less enthusiastic on the use of combination immune therapy based on recent findings. Monotherapy with either atezolizumab (A...

What is New on Bladder Cancer Treatment: ASCO GU 2019? - Josh Meeks

Details
Josh Meeks discusses the bladder cancer data from the ASCO GU 2019 meeting that is compelling from the perspective of urologists in this conversation with Alicia Morgans. Biographies: Josh J. Meeks, MD, PhD, Assistant Professor of Urology and Biochemistry and Molecular Genetics at Northwestern University Feinberg School of Medicine, Chicago Illinois Alicia Morgans, MD, MPH , Associate Professor of...

ERAS in Bladder Cancer - Sia Daneshmand

Details
Sia Daneshmand discusses the history of fast-tracked and streamlined post-operative cystectomy care for patients and associated improved outcomes in his conversation with Ashish Kamat. He details the development of the ERAS protocol and the significant milestones that have been realized in this journey to improved patient outcomes after cystectomy. Biographies: Siamak Daneshmand, MD Dr. Sia Danesh...